title: Inhibition of hyaluronan synthesis reduces versican and fibronectin levels in trabecular meshwork cells.
abstract: Hyaluronan (HA) is a major component of the extracellular matrix (ECM) and is synthesized by three HA synthases (HAS). Similarities between the HAS2 knockout mouse and the hdf mutant mouse, which has a mutation in the versican gene, suggest that HA and versican expression may be linked. In this study, the relationship between HA synthesis and levels of versican, fibronectin and several other ECM components in trabecular meshwork cells from the anterior segment of the eye was investigated. HA synthesis was inhibited using 4-methylumbelliferone (4MU), or reduced by RNAi silencing of each individual HAS gene. Quantitative RT-PCR and immunoblotting demonstrated a reduction in mRNA and protein levels of versican and fibronectin. Hyaluronidase treatment also reduced versican and fibronectin levels. These effects could not be reversed by addition of excess glucose or glucosamine or exogenous HA to the culture medium. CD44, tenascin C and fibrillin-1 mRNA levels were reduced by 4MU treatment, but SPARC and CSPG6 mRNA levels were unaffected. Immunostaining of trabecular meshwork tissue after exposure to 4MU showed an altered localization pattern of HA-binding protein, versican and fibronectin. Reduction of versican by RNAi silencing did not affect HA concentration as assessed by ELISA. Together, these data imply that HA concentration affects synthesis of certain ECM components. Since precise regulation of the trabecular meshwork ECM composition and organization is required to maintain the aqueous humor outflow resistance and intraocular pressure homeostasis in the eye, coordinated coupling of HA levels and several of its ECM binding partners should facilitate this process.
authors.affiliation: Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, USA. gregorka@ohsu.edu
authors.forename: Kate E
authors.initials: KE
authors.lastname: Keller
authors.forename: Ying Ying
authors.initials: YY
authors.lastname: Sun
authors.forename: Janice A
authors.initials: JA
authors.lastname: Vranka
authors.forename: Lauren
authors.initials: L
authors.lastname: Hayashi
authors.forename: Ted S
authors.initials: TS
authors.lastname: Acott
mesh_terms: D000818:Animals; D004797:Enzyme-Linked Immunosorbent Assay; D016326:Extracellular Matrix Proteins / Q000235:genetics / Q000378:metabolism; D005353:Fibronectins / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects; D020868:Gene Silencing / Q000187:drug effects; D005944:Glucosamine / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D014453:Glucuronosyltransferase / Q000235:genetics; D000076002:Hyaluronan Synthases; D006820:Hyaluronic Acid / Q000096:biosynthesis* / Q000494:pharmacology; D006821:Hyaluronoglucosaminidase / Q000378:metabolism; D006923:Hymecromone / Q000031:analogs & derivatives / Q000494:pharmacology; D051379:Mice; D021381:Protein Transport / Q000187:drug effects; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013379:Substrate Specificity / Q000187:drug effects; D034421:Sus scrofa; D014129:Trabecular Meshwork / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D014539:Uridine Diphosphate Sugars / Q000494:pharmacology; D053675:Versicans / Q000378:metabolism*
chemical_list: D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D012333:RNA, Messenger; D014539:Uridine Diphosphate Sugars; D053675:Versicans; D006923:Hymecromone; D006820:Hyaluronic Acid; D014453:Glucuronosyltransferase; D000076002:Hyaluronan Synthases; D006821:Hyaluronoglucosaminidase; D005947:Glucose; D005944:Glucosamine